Third Rock Ventures

Third Rock does not accept unsolicited business plans or pitch decks. The firm's partners identify scientific breakthroughs through their academic networks and internal ideation process, then build companies around those discoveries. Entrepreneurs and scientists are recruited as founders after the initial therapeutic hypothesis, IP strategy, and corporate structure have already been designed by Third Rock's internal team.

Third Rock operates as a company-creation platform rather than a conventional fund manager. Portfolio companies are conceived, incorporated, and housed within Third Rock's offices for the first two to three years of development. The firm staffs initial management roles internally before recruiting external CEOs and scientific leadership, effectively functioning as a biotech incubator with dedicated capital rather than an investor selecting among external startups.

Third Rock invests exclusively in biotechnology and life sciences, with particular emphasis on drug discovery, precision medicine, gene therapy, cell therapy, and genomic medicine. The firm has built companies across oncology, rare disease, immunology, and neuroscience. Investments span therapeutic modalities from small molecules to biologics to CRISPR-based gene editing.

The partnership group makes investment decisions collectively. Founding partners Mark Levin, Kevin Starr, and Robert Tepper established the firm, with partners Reid Huber and Jeffrey Tong later joining the leadership. The firm's scientific advisory network, drawn from leading academic medical centers, plays a significant role in evaluating scientific platforms during the company-formation phase.